# Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

> **NCT06496217** · PHASE1 · COMPLETED · sponsor: **MBX Biosciences** · enrollment: 25 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** MBX 2109
- **DRUG:** MBX 2109
- **DRUG:** MBX 2109
- **DRUG:** MBX 2109

## Key facts

- **NCT ID:** NCT06496217
- **Lead sponsor:** MBX Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-13
- **Primary completion:** 2025-09-04
- **Final completion:** 2025-09-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06496217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06496217, "Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06496217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*